<DOC>
	<DOCNO>NCT00684905</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Antihormone therapy , leuprolide bicalutamide , may lessen amount androgen make body . Implant radiation therapy kill tumor cell place material radioactive iodine directly near tumor . Giving leuprolide bicalutamide together implant radiation therapy may kill tumor cell . PURPOSE : This phase II trial study side effect give leuprolide bicalutamide together implant radiation therapy see well work treat patient locally recurrent prostate cancer external-beam radiation therapy .</brief_summary>
	<brief_title>Leuprolide , Bicalutamide , Implant Radiation Therapy Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility patient tolerance interstitial brachytherapy combine androgen-deprivation therapy patient locally recurrent prostate cancer prior external-beam irradiation . - Determine toxicity interstitial brachytherapy combine androgen-deprivation therapy patient . - Determine tumor response interstitial brachytherapy combine androgen-deprivation therapy patient . OUTLINE : Patients receive neoadjuvant therapy comprise leuprolide acetate intramuscularly 3 month oral bicalutamide daily 30 day , begin first day leuprolide acetate administration . Patients undergo interstitial brachytherapy implantation I-125 . Following brachytherapy , patient receive adjuvant leuprolide acetate every 3 month additional 6 month . Quality life assess baseline every treatment follow-up visit . After completion study therapy , patient follow every 3 month 2 year , every 4-6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsyproven adenocarcinoma prostate Locally recurrent disease , define digital rectal examination and/or rise prostatespecific antigen ( PSA ) No evidence nodal distant metastasis ( i.e. , N0 , M0 ) physical examination , bone scan , CT scan pelvis Clinical stage T1cT3a disease time recurrence PSA &lt; 10 ng/mL Prostate volume transrectal ultrasonography &lt; 60 cc Received prior external beam radiotherapy PATIENT CHARACTERISTICS : ECOG performance status 02 WBC ≥ 3,000/μL Platelet count ≥ 90,000/μL Hemoglobin ≥ 10 g/dL Alkaline phosphatase &lt; 2 time normal AST &lt; 2 time normal Normal prothrombin time partial thromboplastin time No significant obstructive urinary symptom ( AUA score ≤ 16 ) No contraindication general anesthesia PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior transurethral resection prostate</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>